NYSE: CHEChemed Corp Stock
$464.91+5.00 (+1.09%)
Updated Jul 14, 2025
CHE Price
$464.91
Fair Value Price
N/A
Market Cap
$6.80B
52 Week Low
$457.44
52 Week High
$623.61
P/E
22.45x
P/B
5.76x
P/S
3.62x
PEG
2.67x
Dividend Yield
0.43%
Revenue
$2.49B
Earnings
$308.74M
Gross Margin
34.8%
Operating Margin
16.57%
Profit Margin
12.4%
Debt to Equity
0.46
Operating Cash Flow
$366M
Beta
0.44
Next Earnings
Jul 22, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CHE Overview
Chemed Corporation participates in two distinct lines of business. Its VITAS Healthcare segment provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the U.S. Its Roto-Rooter segment offers plumbing, drain cleaning, excavation, water restoration, and related services to residential and commercial customers. The company was incorporated in 1970 and is headquartered in Cincinnati, OH.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CHE's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
B
CHE
Ranked#20 of 42
Ranked#20 of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.08 | A | |
| $13.36 | A | |
| $13.16 | A |
Be the first to know about important CHE news, forecast changes, insider trades & much more!
CHE News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CHE scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CHE ($464.91) is trading above its intrinsic value of $174.61, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CHE is good value based on its earnings relative to its share price (22.45x), compared to the US market average (31.22x)
P/E vs Market Valuation
CHE is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more CHE due diligence checks available for Premium users.
Valuation
CHE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
22.45x
Industry
16.1x
Market
31.22x
CHE is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CHE is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CHE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.76x
Industry
4.6x
CHE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CHE price to earnings growth (PEG)
For valuing profitable companies with growth potential
CHE is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
CHE's financial health
Profit margin
Revenue
$646.9M
Net Income
$71.8M
Profit Margin
11.1%
CHE's Earnings (EBIT) of $412.34M... subscribe to Premium to read more.
Interest Coverage Financials
CHE's profit margin (12.4%) has... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.7B
Liabilities
$544.8M
Debt to equity
0.46
CHE's short-term assets ($502.39M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CHE's short-term assets ($502.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CHE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CHE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$32.7M
Investing
-$13.7M
Financing
-$23.5M
CHE's operating cash flow ($365.69M)... subscribe to Premium to read more.
Debt Coverage Financials
CHE vs Medical Care Facility Stocks
Chemed Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.